Table 2 Factors associated with treatment discontinuation. Multivariate regression model in the group of patients with rheumatoid arthritis.
Lack of efficacy | HR | 95% CI | p |
|---|---|---|---|
Sex (ref. male) | 1.14 | (0.98–1.32) | 0.098 |
Age at onset (years) | 0.99 | (0.99–1.00) | 0.002 |
ts/bDMARDs (ref. anti-TNFα) | 0.61 | (0.54–0.70) | < 0.001 |
Time since diagnosis (years) | 0.99 | (0.98–0.99) | < 0.001 |
Line of treatment (ref. first line) | 1.85 | (1.62–2.12) | < 0.001 |
Starting ts/bDMARDs after the year 2014 (ref. ≤ 2014) | 1.19 | (1.05–1.36) | 0.008 |
Adverse events | HR | 95% CI | p |
|---|---|---|---|
Sex (ref. male) | 1.15 | (0.90–1.46) | 0.262 |
Age at onset (years) | 1.01 | (1.00–1.02) | 0.031 |
Charlson comorbidity index | 1.09 | (1.00–1.17) | 0.042 |
Methotrexate (ref. no methotrexate) | 0.84 | (0.69–1.01) | 0.066 |
Starting ts/bDMARDs after the year 2014 (ref. ≤ 2014) | 0.69 | (0.56–0.86) | 0.001 |
